Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 6, 2013, Pages 518-524

  Aust, Stefanie ^a   Pils, Sophie ^a   Polterauer, Stefan ^a   Horvat, Reinhard ^b   Castillo Tong, Dan Cacsire ^a   Pils, Dietmar ^a   Dudek, Grazyna ^a   Schmid, Bernd ^c   Speiser, Paul ^a   Reinthaller, Alexander ^a   Grimm, Christoph ^a,d  

^a Departments of Gynaecology and Gynaecological Oncology   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Hietzing Hospital   (Austria)

^d UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

BAG 1; BAG 3; BAG 4; Bcl 2; Immunohistochemistry; Ovarian cancer; Prognosis

Indexed keywords

BAG 1 PROTEIN; BAG 3 PROTEIN; BAG 4 PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BRIDGED COMPOUNDS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TAXOIDS; TRANSCRIPTION FACTORS;

EID: 84892445155     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318284a053     Document Type: Article

References (27)

1. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415-428.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334-336.
4. Callagy GM, Webber MJ, Pharoah PD, et al. Meta- A nalysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008;8:153.
5. Frenzel A, Grespi F, Chmelewskij W, et al. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis. 2009;14:584-596.
6. Basu A, DuBois G, Haldar S. Posttranslational modifications of Bcl2 family members- A potential therapeutic target for human malignancy. Front Biosci. 2006;11:1508-1521.
7. Emi M, Kim R, Tanabe K, et al. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 2005;7:R940-R952.
8. Elstrand MB, Kleinberg L, Kohn EC, et al. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Int J Gynecol Pathol. 2009;28:211-221.
9. Herod JJ, Eliopoulos AG, Warwick J, et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996;56:2178-2184.
10. Kassim SK, Ali HS, Sallam MM, et al. Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin Biochem. 1999;32:333-338.
11. Hogdall EV, Christensen L, Kjaer SK, et al. Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study. APMIS. 2010;118:557-564.
12. Berker B, Dunder I, Ensari A, et al. Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol. 2002;23:505-510.
13. Doong H, Vrailas A, Kohn EC. What's in the 'BAG'?-A functional domain analysis of the BAG-family proteins. Cancer Lett. 2002; 188:25-32.
14. Cato AC, Mink S. BAG-1 family of cochaperones in the modulation of nuclear receptor action. J Steroid Biochem Mol Biol. 2001;78: 379-388.
15. Turner BC, Krajewski S, Krajewska M, et al. BAG-1: A novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol. 2001;19:992-1000.
16. Townsend PA, Cutress RI, Sharp A, et al. BAG-1 prevents stressinduced long-term growth inhibition in breast cancer cells via a chaperone-dependent pathway. Cancer Res. 2003;63:4150-4157.
17. Nadler Y, Camp RL, Giltnane JM, et al. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res. 2008;10:R35.
18. Virador VM, Davidson B, Czechowicz J, et al. The anti- A poptotic activity of BAG3 is restricted by caspases and the proteasome. PLoS One. 2009;4:e5136.
19. Rosati A, Graziano V, De Laurenzi V, et al. BAG3: A multifaceted protein that regulates major cell pathways. Cell Death Dis. 2011; 2:e141.
20. Zhu H, Liu P, Li J. BAG3: A new therapeutic target of human cancers? Histol Histopathol. 2012;27:257-261.
21. Annunziata CM, Kleinberg L, Davidson B, et al. BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clin Cancer Res. 2007;13:6585-6592.
22. Diebold J, Baretton G, Felchner M, et al. Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol. 1996;105:341-349.
23. Avraam K, Pavlakis K, Papadimitriou C, et al. The prognostic and predictive value of ERCC-1, p53, bcl-2 and bax in epithelial ovarian cancer. Eur J Gynaecol Oncol. 2011;32:516-520.
24. Skirnisdottir I, Seidal T, Gerdin E, et al. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer. 2002;12:265-276.
25. Ozawa F, Friess H, Zimmermann A, et al. Enhanced expression of silencer of death domains (SODD/BAG-4) in pancreatic cancer. Biochem Biophys Res Commun. 2000;271:409-413.
26. Liao Q, Ozawa F, Friess H, et al. The anti- A poptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Lett. 2001;503:151-157.
27. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol. 2009;4: 287-313.